Scholarlink

<p>Clinical translation in glioma and glioblastoma remains inefficient despite advances in computational drug discovery. An underrecognized contributor to this gap is structural degradation of clinical registry metadata. We analyzed the complete set of 2.357 glioma-related clinical trial records available in the WHO ICTRP registry at the time of extraction (3 January 2026). A deterministic Python-based validation pipeline was developed to normalize phase and study-type annotations while distinguishing technical voids, methodological non-applicability, and structurally inconsistent entries. Two quantitative indices were introduced: the Reporting Gap (<InlineEquation ID="IEq1"><EquationSource Format="TEX">\({G}_{q}\)</EquationSource></InlineEquation>), reflecting phase metadata completeness, and the Maturity Ratio (<InlineEquation ID="IEq2"><EquationSource Format="TEX">\({M}_{r}\)</EquationSource></InlineEquation>), describing the balance between early and late translational stages. Phase annotation showed substantial structural degradation, with large fractions of records lacking machine-interpretable phase labels, whereas study-type fields demonstrated high completeness but severe terminological fragmentation. This asymmetry indicates a systemic mismatch between real-world research designs and the classical phase ontology. Consequently, clinically relevant evidence remains invisible to algorithms, which may lead to biased AI-based translational evaluation. The results suggest that semantic validation of registry metadata is a critical prerequisite for robust integration of clinical data into computational drug development cycles.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical registry metadata as a hidden bottleneck in AI-driven drug discovery: a computational audit of translational phase data in glioma research

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月19日

查看全文
  • Iryna Oliynyk

摘要

Clinical translation in glioma and glioblastoma remains inefficient despite advances in computational drug discovery. An underrecognized contributor to this gap is structural degradation of clinical registry metadata. We analyzed the complete set of 2.357 glioma-related clinical trial records available in the WHO ICTRP registry at the time of extraction (3 January 2026). A deterministic Python-based validation pipeline was developed to normalize phase and study-type annotations while distinguishing technical voids, methodological non-applicability, and structurally inconsistent entries. Two quantitative indices were introduced: the Reporting Gap (\({G}_{q}\)), reflecting phase metadata completeness, and the Maturity Ratio (\({M}_{r}\)), describing the balance between early and late translational stages. Phase annotation showed substantial structural degradation, with large fractions of records lacking machine-interpretable phase labels, whereas study-type fields demonstrated high completeness but severe terminological fragmentation. This asymmetry indicates a systemic mismatch between real-world research designs and the classical phase ontology. Consequently, clinically relevant evidence remains invisible to algorithms, which may lead to biased AI-based translational evaluation. The results suggest that semantic validation of registry metadata is a critical prerequisite for robust integration of clinical data into computational drug development cycles.